EA201992746A3 - Рекомбинантные гликопротеиды и их применения - Google Patents

Рекомбинантные гликопротеиды и их применения

Info

Publication number
EA201992746A3
EA201992746A3 EA201992746A EA201992746A EA201992746A3 EA 201992746 A3 EA201992746 A3 EA 201992746A3 EA 201992746 A EA201992746 A EA 201992746A EA 201992746 A EA201992746 A EA 201992746A EA 201992746 A3 EA201992746 A3 EA 201992746A3
Authority
EA
Eurasian Patent Office
Prior art keywords
recombinant
galactosidase
glycoproteins
recombinant glycoproteins
human
Prior art date
Application number
EA201992746A
Other languages
English (en)
Other versions
EA201992746A2 (ru
Inventor
Карен Ли
Кристофер Хванг
Кристин Демария
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of EA201992746A2 publication Critical patent/EA201992746A2/ru
Publication of EA201992746A3 publication Critical patent/EA201992746A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0631—Mammary cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)

Abstract

В настоящем изобретении предлагаются рекомбинантные гликопротеиды (например, рекомбинантные белки -галактозидазы-A человека) с измененным (например, улучшенным) профилем гликозилирования, и фармацевтические композиции и наборы, содержащие один или несколько из таких белков. Также предлагаются способы создания клетки млекопитающего, применимой для экспрессии рекомбинантного гликопротеида (например, рекомбинантной -галактозидазы-A человека), способы получения рекомбинантных гликопротеидов и способы лечения, которые включают в себя введение субъекту по меньшей мере одного из рекомбинантных гликопротеидов (например, рекомбинантного белка -галактозидазы-A человека).
EA201992746A 2013-11-08 2014-10-22 Рекомбинантные гликопротеиды и их применения EA201992746A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361901942P 2013-11-08 2013-11-08

Publications (2)

Publication Number Publication Date
EA201992746A2 EA201992746A2 (ru) 2020-03-31
EA201992746A3 true EA201992746A3 (ru) 2020-06-30

Family

ID=69942796

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992746A EA201992746A3 (ru) 2013-11-08 2014-10-22 Рекомбинантные гликопротеиды и их применения

Country Status (1)

Country Link
EA (1) EA201992746A3 (ru)

Also Published As

Publication number Publication date
EA201992746A2 (ru) 2020-03-31

Similar Documents

Publication Publication Date Title
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201890456A1 (ru) Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
CY1124778T1 (el) Αντισωματα anti-asic1 και χρησεις αυτων
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
EA201491644A1 (ru) Фармацевтические композиции
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
EA201491470A1 (ru) Композиции фактора viii и способы получения и использования подобных
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
CY1123031T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
AR095555A1 (es) Uso terapéutico de los anticuerpos dirigidos al factor de crecimiento de hepatocitos (hgf)
PH12019501108A1 (en) Anti-gitr anti-binding protein and methods of use thereof
EA201790349A1 (ru) Производные 6-алкинил-пиридина в качестве миметиков белка smac
PH12016500708A1 (en) Recombinant glycoproteins and uses thereof
AR095334A1 (es) Composiciones nutricionales que contienen un componente peptídico con propiedades estimulantes de la adiponectina y método para promover un peso corporal saludable
CO2020016105A2 (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
BR112016005899A2 (pt) composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano
WO2013109190A3 (en) Cho-gmt recombinant protein expression
EA201992746A3 (ru) Рекомбинантные гликопротеиды и их применения
EA201591832A1 (ru) Коэкспрессия фактора viii и фактора фон виллебранда
AR111715A1 (es) ANTICUERPOS ANTI-SIRPa